News

Newron Pharmaceuticals is expanding the International Rett Syndrome Burden of Illness Survey to Europe and Australia in partnership with the worldwide Rett patient advocacy community, following strong participation from caregivers and medical professionals in the United States. Launched last November in the U.S., the survey is being extended…

The gleaming new Dutch headquarters of the European Medicines Agency (EMA), fronting Domenico Scarlattilaan in Amsterdam’s suburban Zuidas business district, finally opened for business last month — just over two years after the European Union decided to relocate the EMA to the Netherlands in the wake of Brexit.

The U.S. Food and Drug Administration (FDA) has granted fast track designation to Anavex 2-73 (blarcamesine) for the treatment of Rett syndrome. Fast track designation is intended to accelerate the development and review of experimental therapies aimed at treating serious or life-threatening conditions, with potential to address…

Using several models of Rett syndrome, scientists have discovered a direct, time-dependent relationship between MeCP2 — the protein altered or with lowered levels in most cases of this disorder — and GABAA receptors, which are important for normal communication between nerve cells. The findings suggest that treating Rett…